Skip to content

Study · Observational study · n = 47 · 2021

1 result

Delayed discharge is associated with higher complement C3 levels and a longer nucleic acid-negative conversion time in patients with COVID-19.

Lin P, Chen W, Huang H, Lin Y, Cai M, Lin D, Cai H, Su Z, Zhuang X, Yu X

Scientific reports13 Jan 2021Cited by 14 (Europe PMC)

PMID33441900 (opens in a new tab)PMCIDPMC7806718 (opens in a new tab)DOI10.1038/s41598-021-81010-3 (opens in a new tab)PepBankPUB-33441900
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

To determine factors associated with delayed discharge of hospitalized patients with coronavirus disease (COVID-19). This retrospective cohort study included 47 patients with COVID-19 admitted to three hospitals in Quanzhou City, Fujian Province, China, between January 21, 2020 and March 6, 2020. Univariate and multivariate logistic regression analyses were conducted to identify factors associated with delayed discharge. The median length of hospital stay was 22 days. Patients in the delayed discharge group (length of hospital stay ≥ 21 days, n = 27) were more likely to have diarrhea, anorexia, decreased white blood cell counts, increased complement C3 and C-reactive protein levels, air bronchograms, undergo thymalfasin treatment, and take significantly longer to convert to a severe acute respiratory syndrome coronavirus (SARS-CoV-2) RNA-negative status than those in the control group (length of hospital stay, < 21 days; n = 20). In multivariate logistic regression analysis, the time to SARS-CoV-2 RNA-negative conversion (odds ratio [OR]: 1.48, 95% confidence interval [CI] 1.09-2.04, P = 0.01) and complement C3 levels (OR 1.14 95% CI 1.02-1.27, P = 0.03) were the only risk factors independently associated with delayed discharge from the hospital. Dynamic monitoring of complement C3 and SARS-CoV-2 RNA levels is useful for predicting delayed discharge of patients.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studyOther

    In hospitalized adults with COVID-19, thymalfasin treatment was more common in patients with delayed discharge than in patients discharged earlier.

    In plain wordsIn hospitalized adults with COVID-19, thymalfasin use was more common with longer stays, but it was not an independent risk factor.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseThymalfasin treatment in delayed versus early discharge
    Study

    n = 47

    Comparator
    Length of stay under 21 days
    Outcome group
    Intensive care and hospital outcomes · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    were more likely to have diarrhea, anorexia, decreased white blood cell counts, increased complement C3 and C-reactive protein levels, air bronchograms, undergo thymalfasin treatment
    2 context sentences
    Summary · context
    Patients in the delayed discharge group (length of hospital stay ≥ 21 days, n = 27)
    Summary · context
    This retrospective cohort study included 47 patients with COVID-19 admitted to three hospitals in Quanzhou City, Fujian Province, China, between January 21, 2020 and March 6, 2020.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.